Viking Therapeutics Insider Sold Shares Worth $1,272,000, According to a Recent SEC Filing
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Viking Therapeutics Options Spot-On: On October 25th, 90,685 Contracts Were Traded, With 218.76K Open Interest
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $125
"Weight loss drug newcomer" Viking (VKTX.US) Q3 performance exceeds expectations, VK2735 prospects are unanimously bullish on Wall Street.
viking therapeutics surged on Thursday, as Wall Street has high hopes for its obesity candidate drug VK2735 latest developments, and the company also announced better-than-expected financial data for the third quarter.
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
